8:00 am Chair’s Opening Remarks

8:10 am Development of BAT8001, a HER2 Antibody Drug Conjugate


  • Learn about the ADC, effective against tumors resistant to trastuzumab, that has been developed
  • Assess clinical studies that have determined the effective dose
  • Hear about the GMP compliant production facility that has been constructed to manufacture the commercial product

8:40 am Clinical Updates of DS-1062

Expanding Your ADC Targets Pipeline

9:10 am ABL202: A Novel Antibody-Drug Conjugate Targeting ROR1-Expressing Tumors


  • Examine ROR1; An attracting cancer target that expresses in various cancer including CLL, TNBC, and lung cancer
  • Assess the activity of anti-ROR1 ADC that was tested on various xenograft models
  • Some preclinical results will be presented for further discussion

9:40 am Antibody Targeted Amanitin Conjugates (ATACs)

  • George Badescu Vice President - Scientific Affairs, Heidelberg Pharma


  • Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin
  • This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
  • Learn more about this technology platform that includes Amanitin supply, sitespecific conjugation, demonstrated safety profile and biomarker
  • HDP-101 is the first ATAC directed against BCMA entering Phase I trials in 2020

10:10 am Morning Refreshments & Networking

Looking at & Enhancing Novel Linker Technologies for Improved Conjugation

11:00 am Improving Site-specific Conjugation Linkers & More Druggable ADCs

  • Bruce Han Chief Executive Officer, New Bio Tx


  • Gain an overview of NBT ADC pipeline
  • Explore NBT’s site-specific conjugation technology
  • Evaluate case studies of ADC discovery with site-specific conjugation technology

11:30 am Creating Next Generation ADCs with Industry-Leading DAR Precision, Plasma Stability & Tumor-Selective Linker Payload Activation

  • Jeiwook Chae Chief Business Development Officer/ Vice President, LegoChem Biosciences


  • Showcasing LCB’s novel next-generation site-specific ADC platform technology
  • Demonstrating proprietary cancer-selective linker providing significantly improved therapeutic index
  • Highlighting tumor-specific and ultra-potent DNA-damaging crosslinking payload with superior efficacy and reduced toxicity

12:00 pm Delving into Site-selective Antibody Conjugation


  • Discussing how current ADCs in the market are prepared by random conjugation of drugs
  • Reviewing the 2nd generation of ADC conjugation that require site-directed mutations of antibodies in current clinical use
  • Presenting the 3rd generation of ADC conjugation which does not require mutations of antibodies

12:30 pm Strategically Enhancing Linkers Applications in ADCs

  • Amy Han Director of Research & Development Chemistry, Regeneron


  • Looking at hydrophilic linkers
  • Assesing the impact of pH sensitive linker
  • Exploring a prodrug linker

1:00 pm Lunch & Networking

Addressing Translational Challenges & Updates from the Clinic

2:00 pm Leveraging Multiple Mechanisms of Action to Improve the Therapeutic Index of ADCs


  • Addressing the tumor delivery challenges and payload toxicity limiting the therapeutic index (TI) of ADCs
  • Understanding how antibody optimization, in addition to the linker/payload, can improve delivery and MoA
  • Exploring counter-intuitive strategies, guided by quantitative pharmacology, that can increase the TI of ADCs

2:30 pm Antibody-Drug Conjugate Bioanalytical Strategies & Applications in Nonclinical & Clinical Studies

  • Ling Xu Principal Scientist & Group Leader, Mersana


  • Total antibody and antibody conjugated drug 2-in-1 assay development and validation
  • Review a nonclinical case study
  • PK/PD simultaneous measurement in mouse model using microsampling to support nonclinical studies

3:00 pm Clinical Trial Update of MRG002

  • Mary Hu Chief Executive Officer, Miracogen


  • Examine the ADC landscape in China
  • Review preclinical findings of MRG002
  • Assess preliminary clinical results of MRG002

3:30 pm Degradation Pathway of Enfortumab Vedotin under Various Stress Conditions


  • Quality characterization of Enfortumab Vedotin by orthogonal analytical approach
  • Introduce physicochemical response of Enfortumab Vedotin exposed to forced degradation conditions
  • Compare quality response between unconjugated mAb and conjugated form

4:00 pm Afternoon Break & Networking

Inspiring Innovation in Antibody Drug Conjugates

4:30 pm DS-6157a, A GPR20 Targeting ADC for the Treatment of Gastrointestinal Stromal Tumor (GIST)


  • GPR20 is an orphan GPCR, selectively and abundantly expressed in GIST
  • DS-6157a is a DNA topoisomerase I inhibitor Exatecan-derivative based ADC, entering phase I trial in 2020
  • In preclinical studies, DS-6157a showed antitumor activity and preferable safety profiles

5:00 pm Merck’s Innovative Drug Pipeline & Partnering Strategy

  • Michael Chen Head of External Innovation APAC, Merck Sereno - Beijing


  • Hear about Merck’s global research and development partnering strategy
  • Review their innovative dug pipeline and innovation focus
  • Receive global ADC updates

5:30 pm Efficient Selection & Optimization of the Antibody for Antibody Drug Conjugates

  • Junho Chung Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine


  • Selection of antibody for ADC using machine learning and next-generation sequencing
  • High throughput screening of antibody for ADC using anti-target x hapten bispecific antibody and hapten-conjugated linker payload
  • Optimization of antibody for stability

6:00 pm Chair’s Closing Remarks